(Am J Obstet Gynecol. 2017;216(2):110–120.e6)
Preeclampsia (PE) and fetal growth restriction (FGR) are significant causes of perinatal morbidity and mortality. Responsible for >70,000 maternal deaths worldwide each year, PE is also associated with increased long-term risk for developing cardiovascular disease in both mother and infant. Several studies and meta-analyses have indicated that prophylactic use of low-dose aspirin at ≤16 weeks’ gestation in women at high risk of developing PE could reduce the prevalence of PE and FGR, and several national societies now recommend that women identified as being at high risk of PE receive low-dose aspirin beginning at <16 week’s gestation. The optimal dose of aspirin remains unclear. The present systematic review and meta-analysis sought to determine the dose-response effect of aspirin for the prevention of PE and FGR.